Neurocrine Biosciences Inc

NBIX

Healthcare|Drug Manufacturers - Specialty & Generic|USA

$177.19

-3.48 (-1.93%)

DCF (FCF)

$85.65

Tangible Book

$33.88

Graham Number

$70.17

Earnings Power

$56.09

Clinical Trials (111)

Trial	Conditions	Phase	Status	Enrollment	Design	Drug
NCT07105111 A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor	Schizophrenia, Schizoaffective Disorder	P4	Recruiting	50	Open-label	Valbenazine
NCT04490915 Global Safety and Efficacy Registration Study of Crinecerfont for Congenital Adrenal Hyperplasia	Congenital Adrenal Hyperplasia	P3	Active	182	RCT, Double-blind	Crinecerfont, Placebo
NCT06966401 Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)	Major Depressive Disorder	P3	Recruiting	850	Open-label	NBI-1065845
NCT06911112 NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)	Major Depressive Disorder	P3	Recruiting	200	RCT, Double-blind	NBI-1065845, Placebo
NCT07196501 A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)	Major Depressive Disorder	P3	Recruiting	550	RCT, Double-blind	NBI-1065845, Placebo
NCT04806451 Global Safety and Efficacy Registration Study of Crinecerfont in Pediatric Participants With Classic Congenital Adrenal Hyperplasia (CAHtalyst Pediatric Study)	Congenital Adrenal Hyperplasia	P3	Active	103	RCT, Double-blind	Crinecerfont, Placebo
NCT06963021 NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)	Major Depressive Disorder	P3	Recruiting	200	RCT, Double-blind	NBI-1065845, Placebo
NCT06786624 Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)	Major Depressive Disorder	P3	Recruiting	200	RCT, Double-blind	NBI-1065845, Placebo
NCT07105098 NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia	Schizophrenia	P3	Recruiting	284	RCT, Double-blind	NBI-1117568, Placebo
NCT06963034 NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia	Schizophrenia	P3	Recruiting	284	RCT, Double-blind	NBI-1117568, Placebo
NCT07114874 NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia	Schizophrenia	P3	Recruiting	600	Open-label	NBI-1117568
NCT07227818 Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia	Schizophrenia	P3	Recruiting	560	RCT, Double-blind	NBI-1117568, Placebo
NCT07288320 An Assessment of Efficacy, Safety, and Pharmacokinetics of NBI-1117568 in Adults With Bipolar I Disorder With Current Mania	Bipolar I Disorder, Mania	P2	Recruiting	150	RCT, Double-blind	NBI-1117568, Placebo
NCT07365462 Efficacy, Safety, and Tolerability of NBI-1065890 Versus Placebo in Adults With Tardive Dyskinesia	Tardive Dyskinesia	P2	Recruiting	100	RCT, Double-blind	NBI-1065890, Placebo
NCT07288333 Evaluation of NBI-1117570 in Inpatient Adults With Schizophrenia	Schizophrenia	P2	Recruiting	120	RCT, Double-blind	NBI-1117570, Placebo
NCT05207085 Efficacy of Valbenazine for the Treatment of Trichotillomania in Adults	Trichotillomania (Hair-Pulling Disorder)	P2	Recruiting	20	RCT, Double-blind	Valbenazine Oral Capsule
NCT07187375 Pharmacokinetics, Safety and Tolerability of Crinecerfont in Participants With Congenital Adrenal Hyperplasia Who Are Less Than 2 Years Old	Congenital Adrenal Hyperplasia	P2	Active	7	Open-label	Crinecerfont
NCT06107829 Valbenazine Treatment of Tardive Dyskinesia in Adults With Intellectual/Developmental Disabilities	Tardive Dyskinesia, Intellectual Disability	P4	Withdrawn	—	Open-label	Valbenazine Oral Capsule
NCT03891862 Persistence of Effect and Safety of Valbenazine for the Treatment of Tardive Dyskinesia	Tardive Dyskinesia (TD)	P4	Completed	135	RCT, Double-blind	Valbenazine, Placebo oral capsule
NCT03698331 The Potential for Clinical Dependence and Withdrawal Symptoms Associated With Valbenazine	Tardive Dyskinesia (TD)	P4	Completed	89	RCT, Double-blind	Valbenazine, Placebo oral capsule
NCT05859698 Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive Dyskinesia	Schizophrenia, Schizoaffective Disorder	P4	Completed	59	Open-label	Valbenazine
NCT05206513 Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy	Dyskinesia, Cerebral Palsy	P3	Completed	86	RCT, Double-blind	Placebo, Valbenazine
NCT00525941 An Exploratory Study of NBI-34060 Capsules and Next Day Functioning	Insomnia	P3	Withdrawn	—	Single-blind	NBI-34060
NCT03532022 Open-label Comparison of Chronocort® Versus Standard Glucocorticoid Replacement Therapy	Congenital Adrenal Hyperplasia	P3	Withdrawn	—	RCT, Open-label	Chronocort®, Standard Care
NCT05063994 Comparison of Chronocort Versus Standard Hydrocortisone Replacement Therapy in Participants Aged 16 Years and Over With Congenital Adrenal Hyperplasia	Congenital Adrenal Hyperplasia	P3	Completed	55	RCT, Double-blind	Chronocort, Cortef
NCT02736955 Rollover Study for Continuing Valbenazine (NBI-98854) Administration for the Treatment of Tardive Dyskinesia	Tardive Dyskinesia	P3	Completed	161	Open-label	Valbenazine
NCT04102579 Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Chorea Associated With Huntington Disease	Chorea, Huntington	P3	Completed	128	RCT, Double-blind	Valbenazine, Placebo
NCT02274558 A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia	Tardive Dyskinesia	P3	Completed	234	RCT, Double-blind	NBI-98854, Placebo
NCT03062280 A Study of the Efficacy, Safety and Tolerability of Chronocort in Treating CAH	Congenital Adrenal Hyperplasia	P3	Completed	91	Open-label	Hydrocortisone
NCT02716818 Comparison of Chronocort® With Standard Glucocorticoid Therapy in Patients With Congenital Adrenal Hyperplasia	Congenital Adrenal Hyperplasia	P3	Completed	122	RCT, Open-label	Chronocort®, standard glucocorticoid therapy
NCT02405091 Safety and Tolerability Study of NBI-98854 for the Treatment of Tardive Dyskinesia	Tardive Dyskinesia	P3	Completed	167	Open-label	NBI-98854
NCT02733367 Extension Study for Patients Entered Into Study Infacort 003	Adrenal Insufficiency	P3	Completed	18	Open-label	Infacort®
NCT05110157 Journey Study: Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment for Schizophrenia	Schizophrenia	P3	Completed	442	RCT, Double-blind	Placebo, Valbenazine
NCT04400331 Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated With Huntington Disease	Chorea, Huntington	P3	Completed	154	Open-label	Valbenazine
NCT02720952 Treatment of Adrenal Insufficiency in Children	Adrenal Insufficiency	P3	Completed	24	Open-label	Infacort®
NCT06312189 Long-term Study to Evaluate Safety and Tolerability of Valbenazine in Participants With Chorea Associated With Huntington Disease in Canada	Chorea, Huntington	P3	By Invite	7	Open-label	Valbenazine
NCT05654870 Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as an Adjunctive Treatment for Schizophrenia	Schizophrenia	P3	Terminated	8	RCT, Double-blind	Valbenazine, Placebo
NCT00232167 Study Of Indiplon/Placebo With Sertraline In Insomnia Co-Existing With Depression	Insomnia, Depression	P3	Terminated	380	RCT, Double-blind	Indiplon, Sertraline
NCT01735617 Pilot Study to Characterize and Examine the Pharmacokinetics and Efficacy of Chronocort® in Adults With CAH	Endocrine Disease, Adrenal Insufficiency	P2	Completed	16	Open-label	Hydrocortisone Modified Release Capsules
NCT03444038 Open-Label Safety and Tolerability Study of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome	Tourette Syndrome	P2	Completed	85	Open-label	Valbenazine
NCT04873869 Study to Evaluate NBI-921352 as Adjunctive Therapy in Subjects With SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE)	SCN8A Developmental and Epileptic Encephalopathy Syndrome	P2	Terminated	8	RCT, Double-blind	NBI-921352, Placebo
NCT05203341 Study to Assess the Efficacy and Safety of NBI-1065845 in Adults With Major Depressive Disorder (MDD)	Major Depressive Disorder	P2	Completed	183	RCT, Double-blind	Placebo, NBI-1065845
NCT01393600 NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder	Tardive Dyskinesia	P2	Completed	37	RCT, Double-blind	NBI-98854, NBI-98854, Placebo
NCT01267188 Efficacy and Safety of NBI-98854 in Subjects With Tardive Dyskinesia	Tardive Dyskinesia	P2	Completed	10	Open-label	NBI-98854
NCT07536269 Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Crinecerfont in Participants With Classic Congenital Adrenal Hyperplasia (CAH) Who Are Less Than 4 Years Old	Congenital Adrenal Hyperplasia	P2	Not Yet Recruiting	20	Open-label	Crinecerfont
NCT04880616 Safety, Efficacy, and Tolerability of NBI-827104 for the Treatment of Essential Tremor	Essential Tremor	P2	Completed	31	RCT, Double-blind	NBI-827104, Placebo
NCT03382639 A Study to Evaluate 3 Dose Levels of Luvadaxistat of Adults With Negative Symptoms of Schizophrenia	Schizophrenia	P2	Completed	256	RCT, Double-blind	Luvadaxistat, Placebo
NCT03325010 Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome	Tourette Syndrome	P2	Completed	127	RCT, Double-blind	Valbenazine, Placebo oral capsule
NCT01688037 NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)	Tardive Dyskinesia	P2	Completed	109	RCT, Double-blind	NBI-98854, NBI-98854, Placebo
NCT04045145 Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-74788 (Crinecerfont) in Pediatric Participants With Congenital Adrenal Hyperplasia	CAH - Congenital Adrenal Hyperplasia	P2	Completed	8	Open-label	Crinecerfont
NCT05159908 A Study to Investigate How Effective, Safe and Tolerable the Drug NBI-921352 is When Used With Anti-seizure Medications in Adults With Focal Onset Seizures	Focal Onset Seizure, Focal Onset Epilepsy	P2	Completed	101	RCT, Double-blind	NBI-921352, Placebo
NCT01733121 NBI-98854 Dose Titration Study for the Treatment of Tardive Dyskinesia	Tardive Dyskinesia	P2	Completed	102	RCT, Double-blind	NBI-98854, NBI-98854, Placebo
NCT03319953 A Randomized, Double-Blind, Placebo Controlled, Two-Period Cross-Over, Proof of Activity Study to Evaluate the Effects of TAK-041 on Motivational Anhedonia as Add-On to Antipsychotics in Participants With Stable Schizophrenia	Stable Schizophrenia	P2	Completed	23	RCT, Double-blind	TAK-041, Placebo, Second Generation Antipsychotics (SGA)
NCT03359785 A Study to Evaluate Multiple Oral Doses of Luvadaxistat in Adults With Schizophrenia	Schizophrenia	P2	Completed	31	RCT, Double-blind	Luvadaxistat, Matching Placebo
NCT03214588 Efficacy, Tolerability, and Pharmacokinetics of Multiple Doses of Oral TAK-831 in Adults With Friedreich Ataxia	Friedreich Ataxia	P2	Completed	67	RCT, Double-blind	TAK-831, TAK-831 Placebo
NCT02581865 Safety and Efficacy Study of NBI-98854 in Adults With Tourette Syndrome	Tourette Syndrome	P2	Completed	124	RCT, Double-blind	NBI-98854, Placebo
NCT02679079 Safety and Efficacy Study of NBI-98854 in Children and Adolescents With Tourette Syndrome	Tourette Syndrome	P2	Completed	98	RCT, Double-blind	NBI-98854, Placebo
NCT05301894 Extension Study to Evaluate NBI-827104 in Pediatric Participants With Epileptic Encephalopathy With Continuous Spike-and-Wave During Sleep	Epileptic Encephalopathy, Continuous Spike and Wave During Sleep	P2	Terminated	19	Open-label	NBI-827104
NCT07111988 Valbenazine in Obsessive Compulsive Disorder	Obsessive-Compulsive Disorder	P2	Not Yet Recruiting	30	RCT, Double-blind	Valbenazine, Placebo
NCT05182476 Study to Evaluate the Efficacy, Safety, and Tolerability of Luvadaxistat in Participants With Cognitive Impairment Associated With Schizophrenia	Schizophrenia	P2	Terminated	216	RCT, Double-blind	Placebo, Luvadaxistat
NCT03525886 Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-74788 in Adults With Congenital Adrenal Hyperplasia	CAH - Congenital Adrenal Hyperplasia	P2	Completed	18	Open-label	NBI-74788
NCT00519818 Comparison of Two Forms of Hydrocortisone in Patients With Congenital Adrenal Hyperplasia	Congenital Adrenal Hyperplasia, 21-Hydroxylase Deficiency	P1P2	Completed	20	Open-label	Chronocort, Cortef
NCT00014677 NBI-3001 Followed by Surgery in Treating Patients With Recurrent Glioblastoma Multiforme	Brain and Central Nervous System Tumors	P2	Completed	—	—	interleukin-4 PE38KDEL cytotoxin
NCT03732534 Rollover Study for Continuing NBI-98854 Administration in Pediatric Subjects With Tourette Syndrome	Tourette Syndrome	P2	Terminated	6	Open-label	NBI-98854
NCT05222152 Chronocort Versus Plenadren Replacement Therapy in Adults With Adrenal Insufficiency	Primary Adrenal Insufficiency	P2	Completed	58	RCT, Double-blind	Chronocort, Plenadren
NCT02879578 Safety and Tolerability Study of NBI-98854 for the Treatment of Subjects With Tourette Syndrome	Tourette Syndrome	P2	Completed	155	Open-label	Valbenazine
NCT03530293 Safety and Efficacy of NBI-98854 in Pediatric Subjects With Tourette Syndrome	Tourette Syndrome	P2	Terminated	81	RCT, Double-blind	Valbenazine, Placebo oral capsule
NCT05165394 Study to Evaluate the Efficacy and Safety of Once-Weekly Oral NBI-1065846 in the Treatment of Anhedonia in MDD	Anhedonia, Major Depressive Disorder	P2	Completed	93	RCT, Double-blind	Placebo, NBI-1065846
NCT00079495 Evaluation of an Altered Peptide Ligand (NBI-5788) in Patients With Relapsing Multiple Sclerosis (MS)	Multiple Sclerosis	P2	Completed	150	RCT, Double-blind	NBI-5788
NCT05226780 Extension Study to Evaluate How Safe and Tolerable NBI-921352 is as an Adjunctive Therapy for Participants With SCN8A-DEE	SCN8A Developmental and Epileptic Encephalopathy Syndrome	P2	Terminated	8	Open-label	NBI-921352
NCT05493293 Extension Study to Evaluate the Safety and Tolerability of NBI-921352 When Used With Anti-seizure Medications in Adults With Focal Onset Seizures	Focal Onset Seizure, Focal Onset Epilepsy	P2	Terminated	82	Open-label	NBI-921352
NCT05545111 Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-1117568 in Adults With Schizophrenia	Schizophrenia	P2	Completed	210	RCT, Double-blind	NBI-1117568, Placebo
NCT04625101 Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-827104 in Pediatric Subjects With Epileptic Encephalopathy With Continuous Spike-and-Wave During Sleep	Epileptic Encephalopathy, Continuous Spike and Wave During Sleep	P2	Completed	24	RCT, Double-blind	NBI-827104, Placebo
NCT06267846 A Study to Evaluate the Efficacy and Safety of NBI-1070770 in Adults With Major Depressive Disorder	Major Depressive Disorder	P2	Completed	73	RCT, Double-blind	NBI-1070770, Placebo
NCT01973543 Safety Study of AADC Gene Therapy (VY-AADC01) for Parkinson's Disease	Parkinson's Disease	P1	Completed	15	Single-blind	VY-AADC01
NCT00039052 Intravenous Interleukin-4 PE38KDEL Cytotoxin in Treating Patients With Recurrent or Metastatic Kidney Cancer, Non-Small Cell Lung Cancer, or Breast Cancer	Breast Cancer, Kidney Cancer	P1	Completed	—	—	interleukin-4 PE38KDEL cytotoxin
NCT01403038 An Open-label Study of the Effects of Elagolix in Adult Premenopausal Females	Folliculogenesis	P1	Completed	216	RCT, Open-label	Elagolix, Elagolix, Elagolix, Elagolix, Elagolix, Elagolix, elagolix
NCT02349503 Safety, Pharmacokinetics and Pharmacodynamics of NBI-77860 in Adolescent Females With Congenital Adrenal Hyperplasia	Congenital Adrenal Hyperplasia	P1	Withdrawn	—	Open-label	NBI-77860, NBI-77860, NBI-77860
NCT03178214 Bioavailability of Infacort When Administered Onto Food Compared to Direct Oral Administration	Adrenal Insufficiency	P1	Completed	19	RCT, Open-label	Infacort
NCT01910480 Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of NBI-98854 in Healthy Subjects	Effect of Ketoconazole on the PK of NBI-98854 in Healthy Subjects	P1	Completed	24	Open-label	NBI-98854 50 mg capsule once daily, Ketoconazole 400 mg (200 mg twice daily)
NCT03311932 A Study of Infacort® Versus Cortef® in Healthy Adult Male and Female Subjects	Adrenal Insufficiency	P1	Completed	51	RCT, Open-label	Infacort®, Cortef®
NCT01960530 An Investigational Study of Hydrocortisone	Adrenal Insufficiency	P1	Completed	14	RCT, Open-label	Hydrocortisone granules, Hydrocortisone Tablet, i.v. Hydrocortisone Injection
NCT00873561 A Study to Evaluate NBI-6024 in Adult and Adolescent Patients With New Onset of Type 1 Diabetes Mellitus	Type 1 Diabetes Mellitus	P1	Completed	188	RCT, Double-blind	NBI-6024
NCT04234672 A Study to Assess Absolute Bioavailability (ABA) of TAK-831 and to Characterize Mass Balance, Pharmacokinetics (PK), Metabolism, and Excretion of [14C]TAK-831 in Male Healthy Participants	Healthy Volunteers	P1	Completed	6	Open-label	TAK-831 Oral Tablet, [14C]TAK-831 IV Infusion, [14C]TAK-831 Oral Suspension
NCT02966652 Study to Compare DITEST to Testosterone Undecanoate in Adult Men With Hypogonadism	Male Hypogonadism	P1	Completed	25	RCT, Open-label	DITEST, Testosterone undecanoate
NCT02777268 Comparison of Pharmacokinetics of Infacort® Versus Immediate-release Hydrocortisone	Healthy Subjects	P1	Completed	16	RCT, Open-label	Infacort, Hydrocortisone
NCT03051893 A Two-part, Study to Compare the Pharmacokinetics and Dose Proportionality of up to 6 Chronocort Formulations	Adrenal Insufficiency, Congenital Adrenal Hyperplasia	P1	Completed	28	RCT, Open-label	Chronocort
NCT03792672 A Study to Evaluate Central Nervous System (CNS) Pharmacodynamic Activity of TAK-653 in Healthy Participants Using Transcranial Magnetic Stimulation (TMS)	Healthy Volunteers	P1	Completed	24	RCT, Double-blind	TAK-653, Placebo, Ketamine
NCT02959892 A Single-Dose Positron Emission Tomography (PET) Study to Determine the Effect of TAK-041 on Amphetamine-Induced Dopamine Release in the Central Nervous System (CNS)	Healthy Volunteers	P1	Completed	12	Open-label	Amphetamine, TAK -041, [11C] (+)-4-propyl-(+)-4-propyl-9-hydroxynaphthoxazine (PHNO)
NCT03101293 A Study to Evaluate the Effect of Food on the Pharmacokinetics of TAK-831 Tablet Formulation	Healthy Volunteers	P1	Completed	15	RCT, Open-label	TAK-831
NCT03496870 A Study of the Pharmacokinetics, Pharmacodynamics, and Safety of Opicapone in Subjects With Parkinson's Disease Taking Levodopa.	Parkinson Disease	P1	Completed	16	Open-label	Opicapone, Carbidopa Levodopa
NCT03562494 VY-AADC02 for Parkinson's Disease With Motor Fluctuations (RESTORE-1)	Parkinson's Disease	P1	Completed	14	RCT, Double-blind	VY-AADC02
NCT02566759 A TAK-831-1001, Single and Multiple Rising Dose Study in Healthy Participants	Schizophrenia, Cerebellar Ataxia	P1	Terminated	110	RCT, Double-blind	TAK-831 Oral Suspension, TAK-831 Placebo, TAK-831 Tablet
NCT02561156 TAK-653 Escalating Single and Multiple Dose Study in Healthy Participants	Depressive Disorder	P1	Completed	88	RCT, Double-blind	TAK-653 Placebo, TAK-653
NCT03706469 A Study to Evaluate the Relative Bioavailability (BA) and Effect of Food on TAK-831 Tablet Formulations in Healthy Participants	Healthy Volunteers	P1	Completed	16	RCT, Open-label	TAK-831 T2, TAK-831 T3
NCT01916993 Safety, Tolerability, and Pharmacokinetics of a Single Dose of NBI-98854 in Subjects With Mild,Moderate, or Severe Hepatic Insufficiency	Safety, Tolerability, and PK of NBI-98854 in Hepatically Impaired Subjects	P1	Completed	24	Open-label	NBI-98854 50 mg capsule
NCT02716987 Study to Determine D-amino Acid Oxidase Brain Enzyme Occupancy of TAK-831 After Single-dose Oral Administration	Healthy	P1	Completed	20	Open-label	TAK-831, [18F]PGM299
NCT02256475 Safety, Pharmacokinetics, and Pharmacodynamics of NBI-98854 in Children and Adolescents With Tourette Syndrome	Tourette Syndrome	P1	Completed	36	Open-label	NBI-98854
NCT02748694 Phase 1 TAK-041 First-in-Human Safety, Tolerability, and Pharmacokinetics Study	Healthy Volunteers, Schizophrenia	P1	Completed	114	RCT, Double-blind	TAK-041, TAK-041 Placebo
NCT03343327 A Study of Chronocort® Versus Cortef ® in Healthy Adult Male Subjects	Adrenal Insufficiency	P1	Completed	25	RCT, Open-label	Chronocort®, Cortef®
NCT03019614 An Open Label Study in Healthy Volunteers to Compare Chronocort® to Hydrocortisone	Congenital Adrenal Hyperplasia, Adrenal Insufficiency	P1	Completed	30	RCT, Open-label	Hydrocortisone, Chronocort
NCT02408068 Effect of Slow Release Hydrocortisone on Fed & Fasting Volunteers; Immediate Release on Fasting Only	Healthy	P1	Completed	18	RCT, Open-label	Dexamethasone, Chronocort: fasted, Immediate release hydrocortisone: fasted, Chronocort: fed
NCT03687684 Phase 1 Study of TAK-831 in Healthy Adult Asian Subjects	Healthy Volunteers	P1	Completed	40	RCT, Double-blind	TAK-831, Placebo
NCT03065192 Safety and Efficacy Study of VY-AADC01 for Advanced Parkinson's Disease	Idiopathic Parkinson's Disease, Parkinson's Disease	P1	Completed	16	Open-label	VY-AADC01
NCT03224325 A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Multiple Doses of TAK-831 in Healthy Participants	Healthy	P1	Completed	50	RCT, Double-blind	TAK-831 Tablet T2, Placebo, TAK-831 Suspension
NCT05053321 Reduction of Demoralization in Patients With Tardive Dyskinesia After Treatment With Valbenazine	Tardive Dyskinesia	P1	Withdrawn	—	Open-label	Valbenazine
NCT03733496 Observational, Long-term Extension Study for Participants of Prior VY-AADC01 Studies	Parkinson's Disease		Completed	14	—	—
NCT06060444 Evaluating a Telemedicine Neurological Consult Program for Drug-Induced Movement Disorders Using the RE-AIM Framework	Drug-Induced Movement Disorder	N/A	Completed	28	RCT, Open-label	—
NCT07611786 Development of Healthcare Transition for Patients With Congenital Adrenal Hyperplasia	Congenital Adrenal Hyperplasia		Not Yet Recruiting	40	—	—
NCT04787965 Opicapone Treatment Initiation Open-Label Study	Parkinson Disease		Completed	239	—	Opicapone
NCT03062033 Real-World Evaluation Screening Study and Registry of Dyskinesia in Patients Taking Antipsychotic Agents	Tardive Dyskinesia		Unknown	70	—	—